Full Breakdown
Trump-Backed Push to Incorporate AI Diagnostics in U.S. Medicine
6/5/2026, 12:29:31 PM
AI-Driven Diagnosis Enables Clinical-Trial Entry
Last summer, Amy Gleason uploaded 16 years of her daughter Morgan’s medical records into the artificial-intelligence system ChatGPT. The AI model returned a diagnosis that differed from the condition previously identified by physicians. Based on this new assessment, Morgan, a 27-year-old who had spent more than a decade managing a debilitating autoimmune disorder, qualified for enrollment in a clinical trial that had previously been out of reach.
Context: Initiative to Introduce AI Doctors
The episode occurs within a broader effort described in the source as a “Trump-backed push to bring AI doctors into American medicine.” The source does not elaborate on the policy mechanisms, funding streams, or organizational partners involved in this initiative.
Key Participants
- Amy Gleason – Mother who uploaded the medical data.
- Morgan Gleason – 27-year-old patient with a long-standing autoimmune condition.
- ChatGPT – Large-language-model AI used to analyze the uploaded records.
- Unnamed clinical trial – Research study that accepted Morgan after the AI-generated diagnosis.
Chronology of the Interaction
- Summer 2025 – Amy Gleason begins using AI after learning about its capabilities.
- Data upload – 16 years of Morgan’s medical history are entered into ChatGPT.
- AI assessment – ChatGPT produces an alternative diagnosis.
- Trial enrollment – Morgan gains entry to a clinical trial based on the AI-derived assessment.
Quantitative Details
- Patient age: 27 years.
- Duration of autoimmune disease: >10 years.
- Medical record span: 16 years of continuous documentation.
Potential Implications for Healthcare Delivery
The Gleason case illustrates how patient-initiated AI analysis can generate diagnostic suggestions that differ from traditional clinical evaluations. When such suggestions align with eligibility criteria for research studies, they may alter a patient’s access to experimental therapies. The incident also highlights the role of large-language-model tools in interpreting extensive longitudinal health data supplied directly by patients.
Gaps and Unresolved Issues
The source does not provide:
- The specific medical condition identified by ChatGPT.
- Details of the clinical trial’s inclusion criteria or therapeutic focus.
- Any official response from medical institutions, professional societies, or regulatory agencies regarding the use of AI for diagnostic purposes.
- Information on how the AI’s recommendation was validated before influencing trial eligibility.
These omissions limit a comprehensive assessment of the broader Trump-backed initiative’s impact on clinical practice, regulatory oversight, and patient safety.
